Pulse Biosciences (NASDAQ:PLSE) Stock Price Crosses Below 50 Day Moving Average – Here’s Why

Pulse Biosciences, Inc (NASDAQ:PLSE – Get Free Report) shares crossed below its 50-day moving average during trading on Friday. The stock has a 50-day moving average of $51.86 and traded as low as $50.20. Pulse Biosciences shares last traded at $50.44, with a volume of 590,839 shares trading hands.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on PLSE shares. Needham & Company LLC lifted their price target on Pulse Biosciences from $58.00 to $64.00 and gave the company a “buy” rating in a research report on Friday, November 6th. Mizuho set a $65.00 price target on Pulse Biosciences in a research note on Friday, November 6th. BTIG Research started coverage on Pulse Biosciences in a report on Wednesday, September 23rd. They issued a “buy” rating and a $70.00 price objective for the company. Freedom Capital raised Pulse Biosciences to a “strong-buy” rating in a research report on Wednesday, September 9th. Finally, Wall Street Zen lowered Pulse Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, November 7th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Pulse Biosciences currently has an average rating of “Moderate Buy” and an average target price of $66.60.

View Our Latest Stock Analysis on Pulse Biosciences

Pulse Biosciences Stock Performance

The firm’s 50 day moving average is $51.86 and its 200 day moving average is $33.28.

Pulse Biosciences (NASDAQ:PLSE – Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.01). Pulse Biosciences had a negative net margin of 5,603.88% and a negative return on equity of 77.88%. The business had revenue of $0.40 million for the quarter, compared to the consensus estimate of $0.52 million. During the same period in the prior year, the business posted ($0.29) EPS. Pulse Biosciences’s revenue for the quarter was down 54.1% on a year-over-year basis. On average, analysts expect that Pulse Biosciences, Inc will post -1.34 EPS for the current fiscal year.

Insider Buying and Selling at Pulse Biosciences

In related news, COO Liane Teplitsky purchased 1,001 shares of the business’s stock in a transaction that occurred on Tuesday, September 1st. The shares were bought at an average price of $49.95 per share, for a total transaction of $49,999.95. Following the purchase, the chief operating officer directly owned 4,095 shares of the company’s stock, valued at approximately $204,545.25. This represents a 32.35% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In the last quarter, insiders purchased 4,095 shares of company stock valued at $199,931. Corporate insiders own 74.00% of the company’s stock.

Institutional Investors Weigh In On Pulse Biosciences

Several hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. purchased a new stake in shares of Pulse Biosciences in the second quarter worth $40,672,000. Bank of America Corp DE bought a new position in shares of Pulse Biosciences during the second quarter valued at $40,115,000. Panoramic Capital LLC bought a new position in shares of Pulse Biosciences during the second quarter valued at $2,719,000. Bank of New York Mellon Corp purchased a new position in shares of Pulse Biosciences in the 2nd quarter worth about $1,196,000. Finally, Marshall Wace LLP purchased a new position in shares of Pulse Biosciences in the 3rd quarter worth about $1,077,000. 76.95% of the stock is owned by institutional investors.

Pulse Biosciences Company Profile

(Get Free Report)

Pulse Biosciences, Inc. develops medical devices using its proprietary nanosecond pulsed field ablation (nsPFA) technology. The technology delivers very short electrical pulses intended to disrupt targeted cells without relying on heat, with the goal of limiting effects on surrounding tissue. The company is developing nsPFA applications for cardiac electrophysiology and surgical oncology, including devices for tissue ablation. Its earlier CellFX System brought the technology to dermatology for treating certain benign skin lesions, marking an initial commercial application of the platform.

Recommended Stories

Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.